<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="781">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782495</url>
  </required_header>
  <id_info>
    <org_study_id>M12-999</org_study_id>
    <secondary_id>2012-004792-39</secondary_id>
    <nct_id>NCT01782495</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients</brief_title>
  <acronym>CORAL-I</acronym>
  <official_title>Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate chronic Hepatitis C Virus infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir,
      ABT-267 (ABT-450/r/ABT-267) with or without ABT-333 and with or without ribavirin in adult
      transplant recipients with hepatitis C virus (HCV) infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with sustained virologic response 24 weeks post treatment</measure>
    <time_frame>24 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with virologic failure during treatment</measure>
    <time_frame>Treatment Day 1 up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification, after HCV RNA less than the lower limit of quantification or HCV RNA greater than or equal to the lower limit of quantification at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with post-treatment relapse</measure>
    <time_frame>Within 12 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification between the end of treatment and 12 weeks post treatment among subjects completing treatment and with HCV RNA less than the lower limit of quantification at the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>ARM A- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 + ribavirin (RBV) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 + ribavirin (RBV) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM D- Liver transplant recipients with Child Pugh A cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 + RBV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM E- Liver transplant recipients with Child Pugh A cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 + RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM F- Post Liver transplant (&gt;3 months) without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 + RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM G- Post Liver transplant (&gt;3 months) without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM H- Renal transplant recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 + RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM I- Renal transplant recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + ABT-333 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J- GT4-infected non-cirrhotic post liver transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K- GT4-infected with cirrhosis post liver transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 + RBV for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267</intervention_name>
    <description>tablet</description>
    <arm_group_label>ARM A- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F2</arm_group_label>
    <arm_group_label>ARM B- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F3</arm_group_label>
    <arm_group_label>ARM C- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F3</arm_group_label>
    <arm_group_label>ARM D- Liver transplant recipients with Child Pugh A cirrhosis</arm_group_label>
    <arm_group_label>ARM F- Post Liver transplant (&gt;3 months) without cirrhosis</arm_group_label>
    <arm_group_label>ARM G- Post Liver transplant (&gt;3 months) without cirrhosis</arm_group_label>
    <arm_group_label>ARM H- Renal transplant recipients</arm_group_label>
    <arm_group_label>ARM I- Renal transplant recipients</arm_group_label>
    <arm_group_label>Arm J- GT4-infected non-cirrhotic post liver transplant</arm_group_label>
    <arm_group_label>Arm K- GT4-infected with cirrhosis post liver transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>tablet</description>
    <arm_group_label>ARM A- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F2</arm_group_label>
    <arm_group_label>ARM B- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F3</arm_group_label>
    <arm_group_label>ARM C- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F3</arm_group_label>
    <arm_group_label>ARM D- Liver transplant recipients with Child Pugh A cirrhosis</arm_group_label>
    <arm_group_label>ARM F- Post Liver transplant (&gt;3 months) without cirrhosis</arm_group_label>
    <arm_group_label>ARM G- Post Liver transplant (&gt;3 months) without cirrhosis</arm_group_label>
    <arm_group_label>ARM H- Renal transplant recipients</arm_group_label>
    <arm_group_label>ARM I- Renal transplant recipients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (RBV)</intervention_name>
    <description>tablet</description>
    <arm_group_label>ARM A- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F2</arm_group_label>
    <arm_group_label>ARM B- Post Liver transplant (&gt;=12 months) fibrosis score &lt;=F3</arm_group_label>
    <arm_group_label>ARM D- Liver transplant recipients with Child Pugh A cirrhosis</arm_group_label>
    <arm_group_label>ARM E- Liver transplant recipients with Child Pugh A cirrhosis</arm_group_label>
    <arm_group_label>ARM F- Post Liver transplant (&gt;3 months) without cirrhosis</arm_group_label>
    <arm_group_label>ARM H- Renal transplant recipients</arm_group_label>
    <arm_group_label>Arm J- GT4-infected non-cirrhotic post liver transplant</arm_group_label>
    <arm_group_label>Arm K- GT4-infected with cirrhosis post liver transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, at least 18 years of age at the time of screening.

          2. Currently taking an immunosuppressant regimen based on either tacrolimus or
             cyclosporine.

             Corticosteroids such as prednisone or prednisolone are permitted as components of the
             immunosuppressant regimen providing the dose is not more than 10 mg/day.

          3. HCV IFN therapy treatment-na√Øve or -experienced, either pre or post liver or renal
             transplant.

          4. Screening HCV genotype testing indicating infection with genotype 1 or 4 HCV only.

        Exclusion Criteria:

          1. Use of everolimus or sirolimus as part of the immunosuppressive regimen within 2
             months of Screening Visit.

          2. Use of any medications listed below as well as those that are contraindicated for use
             with either ritonavir or RBV within 2 weeks prior to study drugs administration or 10
             half-lives (if known), whichever is longer.

          3. Positive test result for Hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus antibody (HIV Ab).

          4. Documented history of post-transplant complications directly involving the hepatic or
             renal vasculature as appropriate to the organ transplanted, e.g., thrombosis of the
             portal vein, the hepatic artery and/or hepatic vein.

          5. Clinically significant abnormalities, other than HCV infection, in a subject
             post-transplant based upon the medical history, physical examination, vital signs,
             laboratory profile and a 12-lead electrocardiogram (ECG) that make the subject an
             unsuitable candidate for this study in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>115 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Enejosa, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Negro, MS</last_name>
    <phone>847-935-9357</phone>
    <email>christopher.negro@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jim Watson, MS</last_name>
    <phone>847.938.7414</phone>
    <email>jim.watson@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90539</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90538</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 90538, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90535</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90562</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90563</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90536</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 90536, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100055</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125419</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125419, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90533</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 90533, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90537</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 90537, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 96250</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 96250, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123975</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123975, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123435</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123435, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123436</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123436, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90573</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120947</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 120947, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123355</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123355, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Genotype 4</keyword>
  <keyword>Chronic Hepatitis</keyword>
  <keyword>Interferon-Free</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Renal Transplant</keyword>
  <keyword>Liver Transplant</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
